Montelukast Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage chronic asthma and to relieve symptoms of seasonal and perennial allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Teva, a leukotriene receptor antagonist, is indicated for conditions involving airway inflammation and allergic responses.

Asthma (maintenance therapy): reduces frequency of bronchoconstriction episodes and improves overall lung function. Seasonal allergic rhinitis: alleviates nasal congestion, sneezing, and itchy eyes during pollen seasons. Perennial allergic rhinitis: controls year‑round nasal symptoms caused by indoor allergens.

Montelukast may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips, or throat - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic injury or abnormal liver function tests - Mood changes including depression or suicidal thoughts - Anaphylactic reactions

When prescribing Montelukast, clinicians should consider several safety precautions to minimize risk.

Assess asthma control: ensure patient is on appropriate inhaled therapy before adding Montelukast. Monitor for allergic reactions: watch for signs of rash, swelling, or respiratory distress. Review concomitant medications: avoid drugs that strongly induce or inhibit CYP enzymes. Evaluate hepatic function: consider baseline liver tests in patients with liver disease. Use caution in patients with psychiatric history: monitor for mood changes or suicidal ideation. Store at room temperature: keep in the original packaging, protect from moisture and heat.

Montelukast can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, or rifampin: strong CYP3A4 inducers that markedly reduce Montelukast exposure. - Ketoconazole, itraconazole, or other potent CYP3A4 inhibitors: may increase systemic levels and risk of adverse effects. - Warfarin: concurrent use may alter anticoagulant effect; close monitoring required.

Moderate Interactions (Monitor Closely): - Theophylline: possible additive bronchodilator effect; observe for increased side effects. - Beta‑agonists (e.g., albuterol): combined use may enhance bronchodilation but requires symptom monitoring. - Antidepressants or antipsychotics: monitor for potential additive central nervous system effects.